http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 17:29:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26780702.html si-local-file:///var/storage/secattach/20260716/26780702.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26780702.html Thu, 16 Jul 2026 17:29:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26780702.html si-local-file:///var/storage/secattach/20260716/26780702.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26780702.html Thu, 16 Jul 2026 17:29:00 -0400 NXTC O.26593406 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+NextCure+Inc.+%28NXTC%29/26770946.html <p>H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $20.00 price target on NextCure Inc. (NASDAQ: NXTC).</p><p>The analyst commented: "Yesterday, NextCure and Avere Therapeutics (private) announced a definitive merger agreement for an all-stock transaction. Avere will be using NextCure's public market infrastructure to accelerate development of AVR-001, a long-acting cyclin peptide oral IL-23 receptor antagonist currently in development for psoriasis. AVR-001 was licensed from Hansoh (HKG: 3692; not rated) for $120M upfront and up to $2.3B in total economics including milestones and royalties. Phase 1b data of AVR-001 in psoriasis indicated potential for once-weekly oral dosing, creating convenience over http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+NextCure+Inc.+%28NXTC%29/26770946.html Wed, 15 Jul 2026 07:41:53 -0400 NXTC http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26764690.html si-local-file:///var/storage/secattach/20260714/26764690.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26764690.html Tue, 14 Jul 2026 07:03:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26764690.html si-local-file:///var/storage/secattach/20260714/26764690.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++NextCure%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+NextCure%2C+Inc./26764690.html Tue, 14 Jul 2026 07:03:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jul+14/26764662.html si-local-file:///var/storage/secattach/20260714/26764662.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jul+14/26764662.html Tue, 14 Jul 2026 07:01:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jul+14/26764662.html si-local-file:///var/storage/secattach/20260714/26764662.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jul+14/26764662.html Tue, 14 Jul 2026 07:01:00 -0400 NXTC O.26593406 http://www.streetinsider.com/Corporate+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Corporate+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Corporate+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Corporate+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Mergers+and+Acquisitions/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Mergers+and+Acquisitions/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Mergers+and+Acquisitions/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Mergers+and+Acquisitions/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Hot+Corp.+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Hot+Corp.+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Hot+Corp.+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Hot+Corp.+News/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Hot+M+and+A/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Hot+M+and+A/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Hot+M+and+A/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html <p>NextCure, Inc. (Nasdaq: NXTC) and privately held Avere Therapeutics, Inc. have announced a definitive all-stock merger agreement. Upon closing, expected in the second half of 2026, the combined company will operate as Avere Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "AVRX."</p><p>The merger is accompanied by a $320 million private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, Wellington Management, T. Rowe Price Investment Management Inc., RTW Investments, and other institutional investors. The financing includes $251 million in convertible notes to be exchanged for http://www.streetinsider.com/Hot+M+and+A/NextCure+and+Avere+to+merge%2C+targeting+oral+IL-23+therapy/26764070.html Tue, 14 Jul 2026 06:01:14 -0400 AKRO NXTC http://www.streetinsider.com/Press+Releases/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html <p align="center"><em>Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy</em></p> <p align="center"><em>Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001</em></p> <p align="center"><em>Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis</em></p> <p align="center"><em>Company to be led by a seasoned team of biotech executives: http://www.streetinsider.com/Press+Releases/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html Tue, 14 Jul 2026 06:00:00 -0400 AKRO NXTC http://www.streetinsider.com/Press+Releases/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html <p align="center"><em>Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy</em></p> <p align="center"><em>Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001</em></p> <p align="center"><em>Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis</em></p> <p align="center"><em>Company to be led by a seasoned team of biotech executives: http://www.streetinsider.com/Press+Releases/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html Tue, 14 Jul 2026 06:00:00 -0400 AKRO NXTC http://www.streetinsider.com/Globe+Newswire/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html <p align="center"><em>Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy</em></p> <p align="center"><em>Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001</em></p> <p align="center"><em>Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis</em></p> <p align="center"><em>Company to be led by a seasoned team of biotech executives: http://www.streetinsider.com/Globe+Newswire/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html Tue, 14 Jul 2026 06:00:00 -0400 AKRO NXTC http://www.streetinsider.com/Globe+Newswire/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html <p align="center"><em>Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy</em></p> <p align="center"><em>Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001</em></p> <p align="center"><em>Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis</em></p> <p align="center"><em>Company to be led by a seasoned team of biotech executives: http://www.streetinsider.com/Globe+Newswire/NextCure+and+Avere+Therapeutics+Announce+Merger+to+Advance+Once-Weekly+Oral+IL-23+Therapy/26764022.html Tue, 14 Jul 2026 06:00:00 -0400 AKRO NXTC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18/26688549.html si-local-file:///var/storage/secattach/20260625/26688549.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18/26688549.html Thu, 25 Jun 2026 08:01:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18/26688549.html si-local-file:///var/storage/secattach/20260625/26688549.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18/26688549.html Thu, 25 Jun 2026 08:01:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+Houston+John+G/26673242.html si-local-file:///var/storage/secattach/20260622/26673242.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+Houston+John+G/26673242.html Mon, 22 Jun 2026 16:15:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+Houston+John+G/26673242.html si-local-file:///var/storage/secattach/20260622/26673242.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+Houston+John+G/26673242.html Mon, 22 Jun 2026 16:15:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+KABAKOFF+DAVID+S/26673258.html si-local-file:///var/storage/secattach/20260622/26673258.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+KABAKOFF+DAVID+S/26673258.html Mon, 22 Jun 2026 16:15:00 -0400 NXTC O.26593406 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+KABAKOFF+DAVID+S/26673258.html si-local-file:///var/storage/secattach/20260622/26673258.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++NextCure%2C+Inc.++++++++++++For%3A+Jun+18++Filed+by%3A+KABAKOFF+DAVID+S/26673258.html Mon, 22 Jun 2026 16:15:00 -0400 NXTC O.26593406